Shan-Shan Jiang

976 total citations
18 papers, 808 citations indexed

About

Shan-Shan Jiang is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Shan-Shan Jiang has authored 18 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Shan-Shan Jiang's work include Immune Cell Function and Interaction (5 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Shan-Shan Jiang is often cited by papers focused on Immune Cell Function and Interaction (5 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Shan-Shan Jiang collaborates with scholars based in China, United States and United Kingdom. Shan-Shan Jiang's co-authors include Qiu-Zhong Pan, Jing-Jing Zhao, Jian‐Chuan Xia, De-Sheng Weng, Xiaofei Zhang, Qi-Jing Wang, Hong-Xia Zhang, Chang-Long Chen, Ke Pan and Dandan Wang and has published in prestigious journals such as PLoS ONE, Scientific Reports and Stem Cells.

In The Last Decade

Shan-Shan Jiang

18 papers receiving 804 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shan-Shan Jiang China	15	382	365	306	159	89	18	808
Qiu-Zhong Pan China	22	552 1.4×	505 1.4×	442 1.4×	203 1.3×	103 1.2×	26	1.1k
Zhi Dai China	11	246 0.6×	215 0.6×	347 1.1×	214 1.3×	71 0.8×	16	744
Jiaqiang Ma China	13	447 1.2×	494 1.4×	431 1.4×	294 1.8×	85 1.0×	18	1.2k
Carl C. Schimanski Germany	18	718 1.9×	348 1.0×	309 1.0×	139 0.9×	85 1.0×	28	1.1k
Jing-Jing Zhao China	25	813 2.1×	786 2.2×	448 1.5×	244 1.5×	121 1.4×	37	1.5k
Lei Deng China	12	330 0.9×	278 0.8×	219 0.7×	90 0.6×	46 0.5×	25	786
Dominique Bonnier France	15	239 0.6×	132 0.4×	363 1.2×	125 0.8×	103 1.2×	20	736
Qin Luo China	9	307 0.8×	456 1.2×	387 1.3×	235 1.5×	114 1.3×	10	990
Prashanth Prithviraj Australia	13	405 1.1×	192 0.5×	319 1.0×	155 1.0×	55 0.6×	28	753
Natalie Y.L. Ngoi Singapore	17	506 1.3×	131 0.4×	428 1.4×	146 0.9×	18 0.2×	70	919

Countries citing papers authored by Shan-Shan Jiang

Since Specialization

Citations

This map shows the geographic impact of Shan-Shan Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shan-Shan Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shan-Shan Jiang more than expected).

Fields of papers citing papers by Shan-Shan Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shan-Shan Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shan-Shan Jiang. The network helps show where Shan-Shan Jiang may publish in the future.

Co-authorship network of co-authors of Shan-Shan Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Shan-Shan Jiang. A scholar is included among the top collaborators of Shan-Shan Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shan-Shan Jiang. Shan-Shan Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Shu, Pan, Shan-Shan Jiang, Rui Li, et al.. (2024). Hong Guo Ginseng Guo (HGGG) protects against kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome and regulating intestinal flora. Phytomedicine. 132. 155861–155861. 10 indexed citations

Wang, Dandan, Yibing Chen, Jingjing Zhao, et al.. (2019). TES functions as a Mena‐dependent tumor suppressor in gastric cancer carcinogenesis and metastasis. Cancer Communications. 39(1). 3–3. 11 indexed citations

Chen, Chang-Long, Qiu-Zhong Pan, Jing-Jing Zhao, et al.. (2016). PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. OncoImmunology. 5(7). e1176653–e1176653. 51 indexed citations

Zhang, Xiaofei, Ke Pan, De-Sheng Weng, et al.. (2016). Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget. 7(18). 26670–26679. 56 indexed citations

Jiang, Shan-Shan, De-Sheng Weng, Long Jiang, et al.. (2016). The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. Journal of Cancer. 7(6). 626–632. 59 indexed citations

Chen, Chang-Long, Ying Wang, Qiu-Zhong Pan, et al.. (2016). Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget. 7(13). 16248–16261. 22 indexed citations

Zhang, Xiaofei, Jie Chao, Qiu-Zhong Pan, et al.. (2015). Overexpression of WWP1 Promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget. 6(38). 40920–40933. 28 indexed citations

Zhang, Hong-Xia, Shan-Shan Jiang, Xiaofei Zhang, et al.. (2015). Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. Oncotarget. 6(33). 34800–34817. 48 indexed citations

Wang, Ying, Chang-Long Chen, Qiu-Zhong Pan, et al.. (2015). Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. Oncotarget. 7(5). 6323–6334. 26 indexed citations

10.

Jiang, Shan-Shan, Xiao Hai Li, Yin Li, et al.. (2015). A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. Oncotarget. 6(29). 27267–27274. 9 indexed citations

11.

Jiang, Shan-Shan, Yan Tang, Yaojun Zhang, et al.. (2015). A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget. 6(38). 41339–41349. 94 indexed citations

12.

Pan, Qiu-Zhong, Ke Pan, Qi-Jing Wang, et al.. (2014). Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells. Stem Cells. 33(2). 354–366. 56 indexed citations

13.

Zhao, Jing-Jing, Qiu-Zhong Pan, Ke Pan, et al.. (2014). Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. Scientific Reports. 4(1). 5177–5177. 93 indexed citations

14.

Jiang, Shan-Shan, De-Sheng Weng, Qi-Jing Wang, et al.. (2014). Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. Journal of Translational Medicine. 12(1). 273–273. 60 indexed citations

15.

Lü, Lin, Ke Pan, Haixia Zheng, et al.. (2013). IL-17A Promotes Immune Cell Recruitment in Human Esophageal Cancers and the Infiltrating Dendritic Cells Represent a Positive Prognostic Marker for Patient Survival. Journal of Immunotherapy. 36(8). 451–458. 77 indexed citations

16.

Zhao, Jing-Jing, Chun-yu Huang, Qi-Jing Wang, et al.. (2013). Decreased Expression of the FOXO3a Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma Patients. PLoS ONE. 8(10). e78158–e78158. 44 indexed citations

17.

Pan, Qiu-Zhong, Ke Pan, Jing-Jing Zhao, et al.. (2013). Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer Immunology Immunotherapy. 62(11). 1675–1685. 36 indexed citations

18.

Huang, Chun-yu, Jing-Jing Zhao, Lin Lv, et al.. (2013). Decreased Expression of AZGP1 Is Associated with Poor Prognosis in Primary Gastric Cancer. PLoS ONE. 8(7). e69155–e69155. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact